Preclinical and clinical pharmacology of antisense oligonucleotides (Q33770561)

29 July 2017

1 reference

title

Preclinical and clinical pharmacology of antisense oligonucleotides (English)

1 reference

29 July 2017

1 reference

Marcusson EG

1

1 reference

29 July 2017

Yacyshyn BR

series ordinal

2

1 reference

29 July 2017

Shanahan WR Jr

series ordinal

3

1 reference

29 July 2017

Dean NM

series ordinal

4

1 reference

29 July 2017

1 August 1999

1 reference

29 July 2017

Molecular Biotechnology

1 reference

29 July 2017

12

1 reference

29 July 2017

1

1 reference

29 July 2017

1-11

1 reference

https://scigraph.springernature.com/pub.10.1385/mb:12:1:1

29 July 2017

0 references

cites work

Identification of an oligodeoxynucleotide sequence motif that specifically inhibits phosphorylation by protein tyrosine kinases

1 reference

12 December 2020

Nonspecific Suppression of [3H]Thymidine Incorporation by "Control" Oligonucleotides

1 reference

12 December 2020

Enhanced activity of an antisense oligonucleotide targeting murine protein kinase C-alpha by the incorporation of 2'-O-propyl modifications

1 reference

12 December 2020

Inhibition of kinesin synthesis and rapid anterograde axonal transport in vivo by an antisense oligonucleotide

1 reference

12 December 2020

Cancer chemotherapy in older adults. A tolerability perspective

1 reference

12 December 2020

Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide

1 reference

12 December 2020

Pharmacology and toxicology of phosphorothioate oligonucleotides in the mouse, rat, monkey and man.

1 reference

12 December 2020

In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides.

1 reference

12 December 2020

Specific inhibition of IgE antibody production by an antisense oligodeoxynucleotide oligomer (Oligostick).

1 reference

12 December 2020

Control of gene expression by oligonucleotides covalently linked to intercalating agents.

1 reference

12 December 2020

Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice

1 reference

12 December 2020

Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide

1 reference

12 December 2020

Synthesis of phosphorothioate-methylphosphonate oligonucleotide co-polymers

1 reference

12 December 2020

2'-O-aminopropyl ribonucleotides: a zwitterionic modification that enhances the exonuclease resistance and biological activity of antisense oligonucleotides

1 reference

12 December 2020

Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo

1 reference

12 December 2020

Hepatotoxicity of chemotherapeutic and oncologic agents

1 reference

12 December 2020

Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey

1 reference

12 December 2020

Comparative evaluation of seven oligonucleotide analogues as potential antisense agents.

1 reference

12 December 2020

Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid

1 reference

12 December 2020

Anti-sense oligodeoxynucleotides--promises and pitfalls

1 reference

12 December 2020

Nonselective inhibition by antisense oligonucleotides of cytosine arabinoside action

1 reference

12 December 2020

Antisense aims for a renaissance

1 reference

12 December 2020

Uniformly modified 2'-deoxy-2'-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets

1 reference

12 December 2020

Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats.

1 reference

12 December 2020

Evidence for a functional kit receptor in melanoma, breast, and lung carcinoma cells.

1 reference

12 December 2020

Oligodeoxynucleotides as inhibitors of gene expression: a review.

1 reference

12 December 2020

Immune stimulation--a class effect of phosphorothioate oligodeoxynucleotides in rodents

1 reference

12 December 2020

Biologic and therapeutic significance of MYB expression in human melanoma

1 reference

12 December 2020

Functions and structures of ribonuclease H enzymes

1 reference

12 December 2020

Modified antisense oligonucleotides directed against tumor necrosis factor receptor type I inhibit tumor necrosis factor alpha-mediated functions.

1 reference

12 December 2020

Beta 2-integrin/intercellular adhesion molecule (ICAM) expression in the normal human intestine.

1 reference

12 December 2020

Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides

1 reference

12 December 2020

Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate

1 reference

12 December 2020

Proof of mechanism of antisense drugs

1 reference

12 December 2020

Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides

1 reference

12 December 2020

DNA analogues with nonphosphodiester backbones.

1 reference

12 December 2020

Inhibition of interleukin-1 type I receptor expression in human cell-lines by an antisense phosphorothioate oligodeoxynucleotide

1 reference

12 December 2020

Altered expression of alpha 4 beta 7, a gut homing integrin, by circulating and mucosal T cells in colonic mucosal inflammation

1 reference

12 December 2020

Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide

1 reference

12 December 2020

RNase H-independent antisense activity of oligonucleotide N3 '--> P5 ' phosphoramidates.

1 reference

12 December 2020

Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides

1 reference

12 December 2020

Gene therapeutics and gene therapy for cancer

1 reference

12 December 2020

Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity

1 reference

12 December 2020

Selective inhibition of A-Raf and C-Raf mRNA expression by antisense oligodeoxynucleotides in rat vascular smooth muscle cells: role of A-Raf and C-Raf in serum-induced proliferation

1 reference

12 December 2020

Inhibition of c-Fos Protein Expression in Rat Spinal Cord by Antisense Oligodeoxynucleotide Superfusion

1 reference

12 December 2020

Renal toxicity of cancer chemotherapeutic agents in children: ifosfamide and cisplatin

1 reference

12 December 2020

Administration of a phosphorothioate oligonucleotide antisense to murine endogenous retroviral MCF env causes immune effects in vivo in a sequence-specific manner

1 reference

12 December 2020

Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression.

1 reference

12 December 2020

Sugar modified oligonucleotides. I. Carbo-oligodeoxynucleotides as potential antisense agents

1 reference

12 December 2020

Stability of antisense DNA oligodeoxynucleotide analogs in cellular extracts and sera

1 reference

12 December 2020

Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus

1 reference

12 December 2020

Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate oligonucleotides

1 reference

12 December 2020

Mechanism of oligonucleotide release from cationic liposomes

1 reference

12 December 2020

Combinatorial screening and rational optimization for hybridization to folded hepatitis C virus RNA of oligonucleotides with biological antisense activity

1 reference

12 December 2020

Antisense oligonucleotides as therapeutic agents--is the bullet really magical?

1 reference

12 December 2020

Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides.

1 reference

12 December 2020

Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines

1 reference

12 December 2020

Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies

1 reference

12 December 2020

Translation inhibition by phosphorothioate oligodeoxynucleotides in cell-free systems

1 reference

12 December 2020

Inhibition of coagulation by a phosphorothioate oligonucleotide.

1 reference

12 December 2020

BCL-2 antisense therapy in patients with non-Hodgkin lymphoma

1 reference

12 December 2020

Nuclease resistance and antisense activity of modified oligonucleotides targeted to Ha-ras

1 reference

12 December 2020

Facilitating oligonucleotide delivery: helping antisense deliver on its promise

1 reference

12 December 2020

Antisense inhibition of the p65 subunit of NF-kappa B blocks tumorigenicity and causes tumor regression

1 reference

12 December 2020

Inhibition of axonal growth by SNAP-25 antisense oligonucleotides in vitro and in vivo.

1 reference

12 December 2020

Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides

1 reference

12 December 2020

The new frontier: gene and oligonucleotide therapy

1 reference

12 December 2020

Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters.

1 reference

12 December 2020

PKC-epsilon is required for mechano-sensitive activation of ERK1/2 in endothelial cells

1 reference

12 December 2020

A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease.

1 reference

12 December 2020

Backbone modifications in oligonucleotides and peptide nucleic acid systems

1 reference

12 December 2020

Antisense properties of end-modified oligonucleotides targeted to Ha-ras oncogene

1 reference

12 December 2020

Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides

1 reference

12 December 2020

Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA.

1 reference

12 December 2020

Intracellular distribution and mechanism of delivery of oligonucleotides mediated by cationic lipids

1 reference

12 December 2020

Phosphorothioate oligodeoxynucleotides are potent sequence nonspecific inhibitors of de novo infection by HIV

1 reference

12 December 2020

Blocking of heart allograft rejection by intercellular adhesion molecule-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities

1 reference

12 December 2020

Hybridization specificity, enzymatic activity and biological (Ha-ras) activity of oligonucleotides containing 2,4-dideoxy-beta-D-erythro-hexopyranosyl nucleosides

1 reference

12 December 2020

Pharmacokinetics of antisense oligonucleotides

1 reference

12 December 2020

Extraction of information on the buildup and consumption of reactive intermediates from quadruplex DNA assembly time courses

1 reference

12 December 2020

Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice.

1 reference

12 December 2020

Antisense oligonucleotides as therapeutics for malignant diseases.

1 reference

12 December 2020

Identifiers

DOI

10.1385/MB:12:1:1

1 reference

Dimensions Publication ID

29 July 2017

0 references

1 reference